{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:14:40Z","timestamp":1763705680959,"version":"build-2065373602"},"reference-count":65,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Despite advances in supportive and protective therapy for myocardial function, cardiovascular diseases due to antineoplastic therapy\u2014primarily cardiomyopathy associated with contractile dysfunction\u2014remain a major cause of morbidity and mortality. Because of the limitations associated with current therapies, investigators are searching for alternative strategies that can timely recognise cardiovascular damage\u2014thus permitting a quick therapeutic approach\u2014or prevent the development of the disease. Damage to the heart can result from both traditional chemotherapeutic agents, such as anthracyclines, and new targeted therapies, such as tyrosine kinase inhibitors. In recent years, metabolomics has proved to be a practical tool to highlight fundamental changes in the metabolic state in several pathological conditions. In this article, we present the state-of-the-art technology with regard to the metabolic mechanisms underlying cardiotoxicity and cardioprotection.<\/jats:p>","DOI":"10.3390\/ijms20194928","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T03:34:01Z","timestamp":1570419241000},"page":"4928","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-7614","authenticated-orcid":false,"given":"Martino","family":"Deidda","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato-Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Mercurio","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-2865","authenticated-orcid":false,"given":"Alessandra","family":"Cuomo","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Noto","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato-Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Mercuro","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato-Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-1797","authenticated-orcid":false,"given":"Christian","family":"Cadeddu Dessalvi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato-Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10741-016-9564-5","article-title":"Current views on anthracycline cardiotoxicity","volume":"21","author":"Mele","year":"2016","journal-title":"Heart Fail. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10554-016-0987-9","article-title":"Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy","volume":"33","author":"Cadeddu","year":"2017","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2459\/JCM.0000000000000376","article-title":"Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy","volume":"17","author":"Madeddu","year":"2016","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1634\/theoncologist.12-9-1124","article-title":"Early epirubicin-induced myocardial dysfunction revealed by serial tissue doppler echocardiography: Correlation with inflammatory and oxidative stress markers","volume":"12","author":"Mercuro","year":"2007","journal-title":"Oncologist"},{"key":"ref_5","first-page":"e76","article-title":"Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection","volume":"17","author":"Deidda","year":"2016","journal-title":"J. Cardiovasc. Med. (Hagerstown) Spec. Issue Cardiotoxic. Antiblast. Drugs Cardioprot."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijcme.2015.10.001","article-title":"Metabolomics, a promising approach to translational research in cardiology","volume":"9","author":"Deidda","year":"2015","journal-title":"IJC Metab. Endocr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12967-015-0661-3","article-title":"Metabolomic approach to profile functional and metabolic changes in heart failure","volume":"13","author":"Deidda","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart\u2014An engine out of fuel","volume":"356","author":"Neubauer","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/01.CIR.0000023531.22727.C1","article-title":"Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure","volume":"106","author":"Osorio","year":"2002","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"H1538","DOI":"10.1152\/ajpheart.00281.2004","article-title":"Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation","volume":"287","author":"Chandler","year":"2004","journal-title":"Am. J. Physiol Heart Circ. Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1161\/01.HYP.0000144292.69599.0c","article-title":"Mechanisms for increased glycolysis in the hypertrophied rat heart","volume":"44","author":"Nascimben","year":"2004","journal-title":"Hypertension"},{"key":"ref_12","first-page":"55","article-title":"An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive heart failure","volume":"42","author":"Taylor","year":"2001","journal-title":"J. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.bbamcr.2012.08.014","article-title":"Targeting mitochondrial oxidative metabolism as an approach to treat heart failure","volume":"1833","author":"Fillmore","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10557-016-6664-3","article-title":"Drugs that affect cardiac metabolism: Focus on perhexiline","volume":"30","author":"Chong","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1582-4934.2009.00759.x","article-title":"Metabolic modulation and cellular therapy of cardiac dysfunction and failure","volume":"13","author":"Revenco","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pharmthera.2017.08.001","article-title":"Cardiac metabolism\u2014A promising therapeutic target for heart failure","volume":"182","author":"Noordali","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","article-title":"The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase","volume":"86","author":"Kantor","year":"2000","journal-title":"Circ. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ehj.2004.02.018","article-title":"Metabolic manipulation in ischaemic heart disease, a novel approach to treatment","volume":"25","author":"Lee","year":"2004","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/aps.2010.31","article-title":"Improvement of mechanical heart function by trimetazidine in db\/db mice","volume":"31","author":"Li","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1021\/jm0605029","article-title":"Discovery of potent and orally available malonyl-coa decarboxylase inhibitors as cardioprotective agents","volume":"49","author":"Cheng","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000356471","article-title":"Effect of inhibiting malonyl-coa decarboxylase on cardiac remodelling after myocardial infarction in rats","volume":"127","author":"Wu","year":"2014","journal-title":"Cardiology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1071-9164(00)00011-7","article-title":"Mitochondrial respiratory chain activity in idiopathic dilated cardiomyopathy","volume":"6","author":"Quigley","year":"2000","journal-title":"J. Card. Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1128\/MCB.20.5.1868-1876.2000","article-title":"The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes","volume":"20","author":"Vega","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0008-6363(00)00241-8","article-title":"Mitochondrial pathology in cardiac failure","volume":"49","author":"Goldenthal","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1440-1681.2002.03655.x","article-title":"Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart","volume":"29","author":"Lehman","year":"2002","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1113\/jphysiol.2003.055095","article-title":"Energy metabolism in heart failure","volume":"555","author":"Garnier","year":"2004","journal-title":"J. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10086","DOI":"10.1073\/pnas.0603615103","article-title":"Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha","volume":"103","author":"Arany","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.3892\/mmr.2015.4466","article-title":"Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate","volume":"12","author":"Li","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.106.116871","article-title":"Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure","volume":"321","author":"Labinskyy","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10741-014-9457-4","article-title":"Mitochondrial oxidative metabolism and uncoupling proteins in the failing heart","volume":"20","author":"Akhmedov","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(04)17402-3","article-title":"Uncoupling proteins in human heart","volume":"364","author":"Murray","year":"2004","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1152\/physrev.2000.80.3.1107","article-title":"Creatine and creatinine metabolisms","volume":"80","author":"Wyss","year":"2000","journal-title":"Physiol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"H1319","DOI":"10.1152\/ajpheart.2001.281.3.H1319","article-title":"Mitochondrial ATPase and high-energy phosphates in failing hearts","volume":"281","author":"Liu","year":"2001","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0140-6736(91)91838-L","article-title":"Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy","volume":"338","author":"Conway","year":"1991","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/01.CIR.100.20.2113","article-title":"Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: A compensatory role for the parallel loss of creatine","volume":"100","author":"Shen","year":"1999","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1006876031121","article-title":"Human myocardial ATP content and in vivo contractile function","volume":"180","author":"Starling","year":"1998","journal-title":"Mol. Cell. Biochem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0735-1097(02)02160-5","article-title":"Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy","volume":"40","author":"Beer","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/01.CIR.94.8.1894","article-title":"Creatine kinase system in failing and nonfailing human myocardium","volume":"94","author":"Nascimben","year":"1996","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tem.2014.11.001","article-title":"Is AMPK the savior of the failing heart?","volume":"26","author":"Kim","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1161\/CIRCRESAHA.111.255505","article-title":"AMP-activated protein kinase regulation and biological actions in the heart","volume":"111","author":"Zaha","year":"2012","journal-title":"Circ. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1161\/CIRCULATIONAHA.108.798561","article-title":"Metformin prevents progression of heart failure in dogs: Role of amp-activated protein kinase","volume":"119","author":"Sasaki","year":"2009","journal-title":"Circulation"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/CIRCRESAHA.108.190918","article-title":"Activation of amp-activated protein kinase by metformin improves left ventricular function and survival in heart failure","volume":"104","author":"Gundewar","year":"2009","journal-title":"Circ. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1021\/tx700335d","article-title":"NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology","volume":"21","author":"Coen","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"D801","DOI":"10.1093\/nar\/gks1065","article-title":"HMDB 3.0\u2014The human metabolome database in 2013","volume":"41","author":"Wishart","year":"2013","journal-title":"Nucl. Acids Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"D603","DOI":"10.1093\/nar\/gkn810","article-title":"HMDB: A knowledgebase for the human metabolome","volume":"37","author":"Wishart","year":"2009","journal-title":"Nucl. Acids Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.chroma.2007.10.066","article-title":"Liquid chromatography and ultra-performance liquid chromatography-mass spectrometry fingerprinting of human urine: Sample stability under different handling and storage conditions for metabonomics studies","volume":"1189","author":"Gika","year":"2008","journal-title":"J. Chromatogr. A"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrcardio.2011.138","article-title":"Metabolomics as a tool for cardiac research","volume":"8","author":"Griffin","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Van den Berg, R.A., Hoefsloot, H.C., Westerhuis, J.A., Smilde, A.K., and van der Werf, M.J. (2006). Centering, scaling, and transformations: Improving the biological information content of metabolomics data. BMC Genom., 7.","DOI":"10.1186\/1471-2164-7-142"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.yjmcc.2006.11.016","article-title":"Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress","volume":"42","author":"Andreadou","year":"2007","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/nbm.1370","article-title":"Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein","volume":"22","author":"Andreadou","year":"2009","journal-title":"NMR Biomed."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.yjmcc.2014.01.007","article-title":"Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism","volume":"69","author":"Andreadou","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Tan, G., Lou, Z., Liao, W., Zhu, Z., Dong, X., Zhang, W., Li, W., and Chai, Y. (2011). Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: A metabonomic method and its application. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027683"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.talanta.2011.11.071","article-title":"Metabonomic study on the cumulative cardiotoxicity of a pirarubicin liposome powder","volume":"89","author":"Cong","year":"2012","journal-title":"Talanta"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1021\/pr501116c","article-title":"Screening, verification, and optimization of biomarkers for early prediction of cardiotoxicity based on metabolomics","volume":"14","author":"Li","year":"2015","journal-title":"J. Proteome Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/jat.3307","article-title":"Early metabolomics changes in heart and plasma during chronic doxorubicin treatment in B6C3F1 mice","volume":"36","author":"Schnackenberg","year":"2016","journal-title":"J. Appl. Toxicol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jchromb.2016.08.042","article-title":"Plasma metabolic profiling analysis of cyclophosphamide-induced cardiotoxicity using metabolomics coupled with UPLC\/Q-TOF-MS and ROC curve","volume":"1033","author":"Yin","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00726-017-2419-0","article-title":"Metabolite signatures of doxorubicin induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes","volume":"49","author":"Chaudhari","year":"2017","journal-title":"Amino Acids"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"QuanJun, Y., GenJin, Y., LiLi, W., YongLong, H., Yan, H., Jie, L., JinLu, H., Jin, L., Run, G., and Cheng, G. (2017). Protective effects of dexrazoxane against doxorubicin-induced cardiotoxicity: A metabolomic study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169567"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1111\/bph.14062","article-title":"Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis","volume":"174","author":"Jensen","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Jensen, B.C., Parry, T.L., Huang, W., Ilaiwy, A., Bain, J.R., Muehlbauer, M.J., O\u2019Neal, S.K., Patterson, C., Johnson, G.L., and Willis, M.S. (2017). Non-Targeted metabolomics analysis of the effects of tyrosine kinase inhibitors sunitinib and erlotinib on heart, muscle, liver and serum metabolism in vivo. Metabolites, 7.","DOI":"10.3390\/metabo7030031"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Yoon, C.S., Kim, H.K., Mishchenko, N.P., Vasileva, E.A., Fedoreyev, S.A., Stonik, V.A., and Han, J. (2018). Spinochrome D attenuates doxorubicin-induced cardiomyocyte death via improving glutathione metabolism and attenuating oxidative stress. Mar. Drugs, 17.","DOI":"10.3390\/md17010002"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"309","DOI":"10.18388\/abp.2018_2568","article-title":"Nuclear magnetic resonance spectroscopy reveals metabolic changes in living cardiomyocytes after low doses of ionizing radiation","volume":"65","author":"Gramatyka","year":"2018","journal-title":"Acta Biochim. Pol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijcard.2015.04.232","article-title":"Cardioprotection by gene therapy: A review paper on behalf of the working group on drug cardiotoxicity and cardioprotection of the Italian Society of Cardiology","volume":"191","author":"Madonna","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1089\/ars.2016.6930","article-title":"From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview","volume":"30","author":"Tocchetti","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.2459\/JCM.0000000000000382","article-title":"Preventing antiblastic drug-related cardiomyopathy: Old and new therapeutic strategies","volume":"17","author":"Cadeddu","year":"2016","journal-title":"J. Cardiovasc. Med. (Hagerstown)"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/19\/4928\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:27:42Z","timestamp":1760189262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/19\/4928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":65,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["ijms20194928"],"URL":"https:\/\/doi.org\/10.3390\/ijms20194928","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2019,10,4]]}}}